Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
NCT06940427Phase 2Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FAPI tracer in idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), sponsored by University of Wisconsin–Madison. Started Nov 2025; status: recruiting.
02
Drugs
FAPI tracer
03
Conditions
idiopathic pulmonary fibrosis (IPF)hypersensitivity pneumonitis (HP)
Beyond the preview
Go deeper on NCT06940427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940427.